DNA Methylation Score as a Biomarker in Newborns for Sustained Maternal Smoking during Pregnancy by Reese, Sarah E et al.
ENVIRONMENTAL
HEALTH 
PERSPECTIVES
Note to readers with disabilities: EHP will provide a 508-conformant 
version of this article upon final publication. If you require a 508-conformant 
version before then, please contact ehp508@niehs.nih.gov. Our staff will work 
with you to assess and meet your accessibility needs within 3 working days.
http://www.ehponline.org
ehp
DNA Methylation Score as a Biomarker in Newborns 
for Sustained Maternal Smoking during Pregnancy
Sarah E. Reese, Shanshan Zhao, Michael C. Wu,  
Bonnie R. Joubert, Christine L. Parr, Siri E. Håberg,  
Per Magne Ueland, Roy M. Nilsen, Øivind Midttun,  
Stein Emil Vollset, Shyamal D. Peddada, Wenche Nystad,  
and Stephanie J. London
http://dx.doi.org/10.1289/EHP333
Received: 22 October 2015
Revised: 8 April 2016
Accepted: 26 May 2016
Published: 21 June 2016
Environ Health Perspect DOI: 10.1289/EHP333 
Advance Publication: Not Copyedited 
 
1 
 
DNA Methylation Score as a Biomarker in Newborns for Sustained 
Maternal Smoking during Pregnancy 
Sarah E. Reese1, Shanshan Zhao2, Michael C. Wu3, Bonnie R. Joubert4, Christine L. Parr1,5, Siri 
E. Håberg6, Per Magne Ueland8,9, Roy M. Nilsen10,11, Øivind Midttun12, Stein Emil Vollset7,10, 
Shyamal D. Peddada2, Wenche Nystad5, and Stephanie J. London1* 
1 Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle 
Park, NC, USA 
2 Biostatistics and Computational Biology Branch, National Institute of Environmental Health 
Sciences, Research Triangle Park, NC, USA 
3 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 
4 Population Health Branch, National Institute of Environmental Health Sciences, Research 
Triangle Park, NC, USA 
5 Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway  
6 Department of Management and Staff, Norwegian Institute of Public Health, Oslo, Norway  
7 Center for Disease Burden, Norwegian Institute of Public Health, Oslo/Bergen, Norway  
8 Department of Clinical Science, University of Bergen, Bergen, Norway  
9 Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway 
10 Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway  
11 Center for Clinical Research, Haukeland University Hospital, Bergen, Norway 
12 Bevital A/S, Bergen, Norway 
*Corresponding Author: Stephanie J. London, NIEHS, PO Box 12233, 111 T.W. Alexander 
Drive, Building 101, Research Triangle Park, NC 27709. Phone: 919-541-5772; Fax: 919-541-
2511; E-mail: london2@niehs.nih.gov 
Environ Health Perspect DOI: 10.1289/EHP333 
Advance Publication: Not Copyedited 
 
2 
 
Short running title: Biomarker in Newborns of in utero Smoke Exposure 
Acknowledgements: We are grateful to all the participating families in Norway who take part in 
this ongoing cohort study. ØM is employed by Bevital A/S, Bergen, Norway. 
Grant information: This work was supported in part by the Intramural Research Program of NIH, 
NIEHS. The Norwegian Mother and Child Cohort Study is supported by the Norwegian Ministry 
of Health and the Ministry of Education and Research, NIH/NIEHS (contract no N01-ES-
75558), NIH/NINDS (grant no.1 UO1 NS 047537-01), and the Norwegian Research 
Council/FUGE (grant no. 151918/S10) and the present project by the Norwegian Research 
Council/BIOBANK (grant no 221097).  
Competing financial interests declaration: There are no competing financial interests.  
Environ Health Perspect DOI: 10.1289/EHP333 
Advance Publication: Not Copyedited 
 
3 
 
Abstract 
Background: Maternal smoking during pregnancy, especially when sustained, leads to 
numerous adverse health outcomes in offspring. Pregnant women disproportionately underreport 
smoking and smokers tend to have lower follow-up rates to repeat questionnaires. Missing, 
incomplete, or inaccurate data on presence and duration of smoking in pregnancy impairs 
identification of novel health effects and limits adjustment for smoking in studies of other 
pregnancy exposures. An objective biomarker in newborns of maternal smoking during 
pregnancy would be valuable. 
Objectives: To develop a biomarker of sustained maternal smoking in pregnancy using common 
DNA methylation platforms.  
Methods: Using a dimension reduction method, we developed and tested a numeric score in 
newborns to reflect sustained maternal smoking in pregnancy from data on cotinine, a short-term 
smoking biomarker measured mid-pregnancy, and Illumina450K cord blood DNA methylation 
from newborns in the Norwegian Mother and Child Cohort Study (MoBa).  
Results: This score reliably predicted smoking status in the training set (N=1,057; 
accuracy=96%, sensitivity=80%, specificity=98%). Sensitivity (58%) was predictably lower in 
the much smaller test set (N=221), but accuracy (91%) and specificity (97%) remained high. 
Reduced birth weight, a well-known impact of maternal smoking, was as strongly related to the 
score as to cotinine. A three site score had lower, but acceptable, performance 
(accuracytrain=82%, accuracytest=83%). 
Conclusions: Our smoking methylation score represents a promising novel biomarker of 
sustained maternal smoking during pregnancy easily calculated with Illumina450K or 
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IlluminaEPIC data. It may help identify novel health impacts and improve adjustment for 
smoking when studying other risk factors with more subtle effects. 
  
Environ Health Perspect DOI: 10.1289/EHP333 
Advance Publication: Not Copyedited 
 
5 
 
Introduction 
Despite years of health warnings and cessation campaigns, smoking during pregnancy remains 
an important public health problem (Murin et al. 2011). Women who smoke during pregnancy 
are more likely to have children with lower birth weight, preterm delivery, reduced lung 
function, asthma, attention deficit hyperactivity disorder (ADHD), orofacial clefts and other 
malformations (US Department of Health and Human Services 2014). Emerging evidence links 
additional health outcomes in children to maternal smoking (Mund et al. 2013). Because of the 
consistent and important effects of maternal smoking on child health, it is crucial to carefully 
adjust for smoking when investigating effects of other in utero environmental exposures that 
may have more subtle effects.  
Various newborn adverse health outcomes related to maternal smoking, including reduced birth 
weight, have been shown to be mitigated by cessation (US Department of Health and Human 
Services 2014), suggesting that sustained smoking during pregnancy rather than simply any 
smoking during pregnancy is the important parameter to assess in epidemiologic studies. Using a 
genome-wide approach (Illumina HumanMethylation450 BeadChip, henceforth Illumina450K), 
Joubert et al. (2012) reported that maternal smoking during pregnancy is associated with 
differential DNA methylation in newborns at specific loci that replicated in a second population. 
Subsequent reports have consistently confirmed and extended these findings (Joubert et al. 
2016). Joubert et al. (2014) subsequently reported that the DNA methylation signals observed in 
newborns reflect sustained smoking, defined by cotinine measured at about 18 weeks of 
gestation, rather than transient smoking; they were not seen when women quit earlier in 
pregnancy.  
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Smoking during pregnancy is generally assessed in epidemiologic studies by questionnaires. 
Studies vary in the number of time points at which smoking information is collected and, even 
when complete histories across pregnancy are sought, missing questionnaire data at one or more 
time points decreases sample size for assessment of sustained smoking. Smokers tend to have 
lower response rates to follow-up questionnaires (Jacobsen and Thelle 1988). While a positive 
self-report of smoking is reliable, pregnant women are more likely to underreport smoking 
compared to women of the same age who are not pregnant (Dietz et al. 2011; Kvalvik et al. 
2012), likely due to the well-known negative impacts of this exposure on the child. Cotinine is 
the best biomarker of smoking status available (Benowitz 1996; Kvalvik et al. 2012), but has a 
half-life of only 17 hours in non-pregnant women (Benowitz 1996) and 9 hours in pregnant 
women (Dempsey et al. 2002).  There have been recent attempts to develop biomarkers of long-
term smoking exposure in adults using the Illumina450K platform (Shenker et al. 2013; Zhang et 
al. 2015). However, this has not been done in newborns to reflect exposure to maternal smoking 
during pregnancy.   
The goal of this paper is to develop, using the Illumina450K methylation platform, a biomarker 
in newborns of sustained smoking by the mother during pregnancy that can be easily applied to 
other newborn studies with either Illumina450K or Illumina Infinium MethylationEPIC 
BeadChip (henceforth IlluminaEPIC) methylation data. A biomarker of this nature will be useful 
in studies of childhood health outcomes to fill in the inevitable missing data on whether or for 
how long a mother smoked, when limited data were collected on timing of smoking, and to 
validate self-reports of non-smoking. While statistical methods exist to fill in missing data, such 
as multiple imputation, these are inferior to a direct and objective biomarker. Further these 
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methods involve assumptions about the random nature of the missing data (Sterne et al. 2009) 
that are unlikely to hold for smoking, especially during pregnancy. We used two existing datasets 
with Illumina450K methylation measured in newborns and cotinine measured in maternal 
plasma during pregnancy to develop and test a methylation score to predict smoking. We also 
examined the association between the resulting methylation score and reduced birth weight, a 
well established consequence of maternal smoking during pregnancy (US Department of Health 
and Human Services 2014).  
Methods 
Study Population 
The Norwegian Mother and Child Cohort Study (MoBa) is a large population-based pregnancy 
study conducted by the Norwegian Institute of Public Health targeting all women who gave birth 
in Norway from 1999 to 2008 (Magnus et al. 2006; Ronningen et al. 2006). Blood samples were 
obtained from the mother during pregnancy and from newborns (cord blood). Here we analyzed 
a subcohort of MoBa participants (born 2002-2004) with Illumina450K methylation data 
measured from newborn DNA and cotinine measured from maternal plasma at about gestational 
week 18 of pregnancy (Joubert et al. 2012). The Illumina450K methylation data were generated 
in two different analytic batches: MoBa1 (N=1,068, generated in 2011) and MoBa2 (N=222, 
generated in 2013). We used the first dataset (MoBa1) analyzed by Joubert et al. (2012), as our 
training set. The second dataset (MoBa2) served as our test dataset.   
Exposure to nicotine from sources other than cigarette smoking could be reflected in cotinine 
levels, but are not expected to generate the same methylation signals (Besingi and Johansson 
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2014); therefore, we excluded the 10 subjects from the training set and one subject from the test 
set who reported use during pregnancy of snuff/chewing tobacco, nicotine gum, nicotine patch, 
or nicotine inhaler. One additional subject was excluded from the training set due to missing 
cotinine data. This left us with 1,057 subjects in the training set and 221 in the test set for 
analyses.  
The MoBa study has been approved by the Regional Committee for Ethics in Medical Research, 
the Norwegian Data Inspectorate, and the Institutional Review Board of the National Institute of 
Environmental Health Sciences. Written informed consent was obtained from all participants. 
Laboratory Measurements 
Cotinine 
Cotinine concentrations were measured in maternal plasma collected at approximately 18 weeks 
gestation (Kvalvik et al. 2012) using liquid chromatography-tandem mass spectrometry at 
BEVITAL AS (www.bevital.no) (Midttun et al. 2009).   
Methylation Data 
We measured DNA methylation in cord blood samples at 485,577 CpG sites using the Infinium 
HumanMethylation450 BeadChip (Bibikova et al. 2011; Sandoval et al. 2011). Bisulfite 
conversion was performed using the EZ-96 DNA methylation kit. All quality control and data 
processing was done as described previously (Joubert et al. 2012). Briefly, samples were omitted 
if the average detection p-value across all probes was less than 0.05 and/or they were labeled as 
failed by Illumina, they were identified as a gender outlier, or they were a blind duplicate of 
another sample included in the dataset. CpGs that were missing chromosome data, were missing 
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more than 10% of data across samples, or were on chromosome X or Y were omitted. Joubert et 
al. (2012) found no evidence of batch effects in these data, which were generated over less than 
four weeks. Beta values, 𝛽𝛽, were calculated in Illumina’s GenomeStudio methylation software as 
the ratio of the intensity of the methylated allele to the sum of the intensities of the methylated 
and unmethylated alleles plus a constant. The beta values were additionally logit transformed to 
obtain the log ratio, ln !
!!!
.  
Definition of Sustained Smoking in this Analysis 
We used the term “sustained smoking” as in our previous report (Joubert et al. 2014) where we 
found that the methylation signals were observed in newborns with mothers in this group but not 
in mothers who quit early in pregnancy. Among the 1,278 pregnancies across the training and 
test sets, we examined the timing of quitting smoking during pregnancy using questionnaire data 
collected at two time points in pregnancy (approximately weeks 17 and 30 of gestation). Among 
these women, 127 reported smoking at the beginning of pregnancy and did not report quitting. 
Among the 253 who reported quitting during pregnancy, there were 54 who did not report in 
which week of pregnancy they quit, 184 who reported quitting by 18 weeks, and 15 who reported 
quitting after 18 weeks. Thus the vast majority of women who reported that they stopped 
smoking during pregnancy did so by 18 weeks. Our cotinine value measured at about 18 weeks 
identifies women who are still smokers at this time point. When considered in combination with 
our questionnaire data, a cotinine value in the active smoking range both reflects smoking into 
the second trimester, as opposed to smoking that stopped early in pregnancy, and, for the vast 
majority of women who smoked at the onset of pregnancy, correlates with smoking through most 
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of pregnancy. We therefore refer to smoking detected by cotinine >56.8 nmol/L (Shaw et al. 
2009) at about 18 weeks or self-reported later in pregnancy (17 or 30 weeks) as “sustained” 
smoking during pregnancy in this analysis. 
Cotinine-based Classification of Sustained Smoking During Pregnancy 
We refer to the smoking variable based solely on cotinine dichotomized at 56.8 nmol/L as 
“cotinine-based sustained smoking.” 
Self-report based Classification of Sustained Smoking During Pregnancy 
The “self-reported sustained smoking” variable was created from data from two questionnaires, 
one administered at about 17 weeks of pregnancy and one administered at about 30 weeks, 
supplemented with information collected from mothers at birth from the Medical Birth Registry 
of Norway (MBRN). This variable classifies mothers who reported that they were sometimes or 
daily smokers as smokers, and mothers who reported that they never smoked, quit before 
pregnancy, or stopped smoking early in pregnancy as non-smokers.  
Combined Classification of Sustained Smoking During Pregnancy 
We also created a “combined sustained smoking” variable that classifies mothers based on 
cotinine levels above 56.8 nmol/L as smokers combined with mothers who self-reported as daily 
smokers whether or not their cotinine value exceeded this threshold. This “combined sustained 
smoking” variable reclassified as smokers ten individuals in the training set and one in the test 
set who were nonsmokers according to the  “cotinine-based sustained smoking” variable.  
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Statistical Methods  
Development of Smoking Biomarker on Training Data 
We performed a genome-wide robust linear regression (Fox and Weisberg 2011) on the training 
set (MoBa1) using the “combined sustained smoking” variable as the dichotomous predictor and 
the log ratios of the DNA methylation data as the response variable. These were non-normalized 
as in Joubert et al. (2012) so as to closely replicate these results. The top 200 most significant 
CpGs were selected, consistent with the sure independent screening approach suggested by Fan 
and Lv (2008). We then cross-referenced the 200 CpGs with lists of potentially problematic 
probes (Chen et al. 2013), including those that have single nucleotide polymorphisms nearby. 
We visually inspected the distributions of all CpGs that overlapped with these lists and removed 
5 CpGs with non-unimodal distributions from further analysis. The remaining 195 CpGs were 
used in the logistic least absolute shrinkage and selection operator (LASSO) model to choose a 
set of CpGs for use in the calculation of the smoking score (Hastie et al. 2009; Tibshirani 1996).  
We used the untransformed methylation beta values as the predictors of maternal smoking 
because it has become more common to analyze Illumina450K data on the natural scale. In 
previous studies, results of classification methods were not significantly different when using 
beta values versus log ratios for large sample sizes (Zhuang et al. 2012). To account for the 
randomness of the LASSO procedure (Hastie et al. 2009; Tibshirani 1996), we performed it 100 
times. After running the 100 iterations, we selected the subset of CpGs that appeared in all 100 to 
choose a robust subset of CpGs that might be more applicable to other studies. A smoking score 
was then calculated as the linear combination of the subset of CpGs and the logistic LASSO 
regression coefficients.  
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Receiver operating characteristic (ROC) analysis (Metz 1978) was used to establish a threshold, 
based on the logistic LASSO regression coefficients, for the smoking methylation score to 
classify newborns according to exposure to a mother with sustained smoking during pregnancy 
using the combined variable described above. We set the threshold to minimize the sum of false 
positives and false negatives with the restriction that the sensitivity had to be at least 80%. False 
positives are subjects misclassified as offspring of smoking mothers, whose mothers did not 
smoke according to their combined self-report and cotinine measurements. False negatives are 
subjects misclassified as offspring of mothers who did not smoke, who appear to smoke based on 
their combined self-report and cotinine values. We calculated the area under the curve (AUC) 
and used the threshold to classify samples and to calculate the accuracy, sensitivity, and 
specificity.  
Validation of Smoking Biomarker on Test Data 
Using the same logistic LASSO regression coefficients and threshold value, we calculated the 
smoking methylation score for the test set (MoBa2) and performed ROC analysis at the threshold 
established above to calculate the accuracy, sensitivity, and specificity. 
Comparing Different Smoking Variables to Train the Score  
Several additional analyses were performed to assess how the LASSO regression results changed 
when using other smoking variables to train the model rather than combined sustained smoking. 
We focused on combined sustained smoking because, although cotinine is an objective measure 
and the best available biomarker of smoking, it is relatively short term. Most pregnant women in 
our study do not smoke heavily and many do not smoke daily. Thus, if a woman refrained from 
smoking on the day of her clinic visit when blood for cotinine was drawn, the value might be in 
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the non-smoking range. Because pregnant women are exceedingly unlikely to claim to be 
smokers when they are not, it seems imprudent to overwrite a positive self-report of smoking 
because of a cotinine value below our cutoff. In addition to this primary smoking variable 
(“combined sustained smoking”), we trained our model using two additional smoking variables: 
“cotinine-based sustained smoking,” which is based only on the cotinine measurement and “self-
reported sustained smoking,” based only on questionnaire data.  
We performed an additional sensitivity analysis using a naïve CpG selection approach including 
only the three loci replicated at strict Bonferroni significance in Joubert et al. (2012) to form the 
smoking methylation score. This approach used the most significant CpG from each of these 
three loci (AHRR, GFI1, and CYP1A1) from our genome-wide analysis and the corresponding 
robust linear regression coefficients to compute the smoking methylation score.  
Illumina recently released the EPIC BeadChip which covers over 850K CpG sites (Moran et al. 
2016). Approximately 42,000 of the Illumina450K CpGs are not included on IlluminaEPIC. 
Because we do not have IlluminaEPIC data, we assessed the performance of the score trained on 
the Ilumina450K data after deleting CpGs that do not overlap between the two platforms.  
The AUC, accuracy, sensitivity, and specificity were used to evaluate the performance of the 
methylation score created in these different additional analyses.  
Birth Weight in Relation to the Different Smoking Variables 
We examined how our methylation score relates to a known newborn health outcome of having a 
mother who smoked during pregnancy. We chose birth weight because of the well-established 
inverse association with maternal smoking during pregnancy (US Department of Health and 
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Human Services 2014). We performed a linear regression analysis to compare the association 
between birth weight and various smoking variables: sustained smoking based on our newly 
created smoking methylation score, cotinine-based sustained smoking, self-reported sustained 
smoking, combined sustained smoking (using both self-report and cotinine), and a self-report 
variable for any (yes or no) smoking during the pregnancy whether sustained or not. We 
appreciate that there is some circularity because we developed the score in the training portion of 
the data using the combined sustained smoking variable as the gold standard.  
The birth weight variable came from the Medical Birth Registry of Norway (MBRN) (Irgens 
2000). Covariates included in all birth weight models were gender, gestational age, maternal 
education, maternal age, parity, and the selection variable for the data set. We also created a 
crude model without the smoking variable for comparison.  
We assessed fit of the birth weight models using likelihood ratio tests (LRT) comparing models 
including a smoking variable to the crude model. We used root mean square error (RMSE) to 
assess how well each model estimated birth weight. The smaller the RMSE the better the model 
estimated birth weight.  
All analyses were performed in R version 3.0.2 (R Core Team 2013) (Packages used: glmnet, 
pROC, MASS, sandwich, and lmtest). 
Results 
The percentage of mothers positive for combined sustained smoking during pregnancy was 
similar in the training and test sets (Training: 13.0%; Test: 14.0%; p-value=0.34; Table 1). 
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Among these smokers, the amount smoked was low (median=5 cigarettes per day) in both the 
training and test sets (Table 1).  
The iterative logistic LASSO AUC cross-validation procedure, a procedure to choose the CpGs 
most predictive of combined sustained smoking, identified 28 CpGs retained in all 100 runs in 
the training set (Supplementary Table S1). As expected, there was substantial overlap of the 
CpGs on this list and those reported by Joubert et al. (2012) – 5 of the original 10 loci were 
identified. The distributions of the calculated smoking methylation score for the training set by 
levels of our combined sustained smoking variable are displayed in Supplementary Figure S1A. 
In the ROC analysis for the training set (N=1,057), the smoking methylation score compared 
well to the combined sustained smoking variable (AUC=0.96; 95% Confidence Interval 
(CI)=[0.95, 0.98]; Supplementary Figure S2). The resulting threshold value for the smoking 
methylation score was -0.37 with an accuracy of 96%, sensitivity of 80% and specificity of 98% 
(Table 2 model c). At this threshold, there were 19 (1.8%) false positives (non-smokers that were 
classified as smokers) and 27 (2.6%) false negatives in the training set.  
For the test set (N=221) the AUC was 0.90 (CI=[0.83, 0.97]; Supplementary Figure S2), using 
the same regression coefficients from the LASSO to calculate the smoking methylation score 
(Supplementary Figure S1B) and the same threshold value for the ROC analysis. As expected, 
the performance of the smoking methylation score was not as high in this much smaller test set 
(Table 2 model c): sensitivity was reduced to 58%, although accuracy (91%) and specificity 
(97%) were only slightly lower than in the training set. In the test set there were 6 (2.7%) false 
positives and 13 (5.9%) false negatives.  
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Additional Analyses 
As expected, cotinine-based sustained smoking and self-reported sustained smoking differed 
slightly (Supplementary Table S2; phi coefficient=0.79 (Training set) and 0.81 (Test set)). 
Therefore, we compared our main analysis  (“combined sustained smoking,” Table 2 model c 
and Supplementary Table S1) to models where we trained the smoking methylation score using 
the “cotinine-based sustained smoking” variable (Table 2 model a and Supplementary Table S3) 
or separately, the “self-reported sustained smoking” variable (Table 2 model b and 
Supplementary Table S4). Table 2 shows the number of CpGs (q) used to calculate the smoking 
methylation score and the results of the ROC analysis for the smoking methylation scores 
calculated using the three different smoking variables. The predictive ability of the smoking 
methylation score was best when trained on the combined sustained smoking. As expected, in all 
models the sensitivity in the smaller test set was substantially reduced compared to the larger 
training set. The specificity remained high, only slightly reduced, for the test set compared to the 
training set.  
The naïve approach using only the three replicated CpGs does not predict smoking status as 
reliably as the LASSO model trained on combined sustained smoking and resulted in lower 
sensitivity and considerably lower specificity in both the training and test sets (Table 2 model d) 
although it had acceptable performance (training set AUC=0.89, test set AUC=0.82). 
Only two of the 28 CpGs identified in the combined sustained smoking score are not included in 
the IlluminaEPIC array (cg00709966 and cg11864574). Leaving these two CpGs out made very 
little difference in the performance of the score (Supplementary Tables S5 and S6). 
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Birth Weight Analysis 
Using linear regression models, we compared the association between birth weight and smoking, 
classified variously as exposed based on the smoking methylation score (12.7% prevalence), 
cotinine-based sustained smoking (12.2%), self-reported sustained smoking (11.6%), combined 
sustained smoking (13.2%), and an additional variable for self-report of any smoking during 
pregnancy whether sustained or not (yes versus no; yes = 28.3%; Supplementary Table S7). 
Supplementary Tables S7 and S8 give descriptive statistics in the training data for the smoking 
variables and covariates included in the models. Table 3 shows the resulting coefficients and 
standard errors from the linear regression models, the Akaike information criterion (AIC), log-
likelihood, and p-value resulting from the likelihood ratio test to the crude model. The RMSE did 
not distinguish much between models (range 444.06-445.62). This is not surprising given that 
maternal smoking leads only to a modest decrement in birth weight, and thus, is not its major 
determinant; in these data the maximum percent of variation explained was 33.2% (range 32.6%-
33.2%). Although the differences were miniscule, the sustained smoking models all performed 
significantly better than the crude model (Table 3) whereas the any smoking variable did not 
perform better than the crude model.  
Discussion 
We developed a novel biomarker in newborns of sustained maternal smoking in pregnancy using 
methylation values in newborns from the Illumina450K platform. This biomarker is a smoking 
methylation score that incorporates the subset of 28 CpGs we found to be most predictive of 
maternal smoking status from a logistic LASSO model.  The sensitivity was high in the training 
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set but lower, as expected, in the much smaller separate test set; however, the specificity 
remained high in both. When we evaluated the relationship with reduced birth weight, a well-
established health effect of maternal smoking, we found that our smoking methylation biomarker 
performs about the same as the cotinine-based sustained smoking, self-reported sustained 
smoking, combined sustained smoking incorporating self-report and cotinine, and substantially 
better than self-report of any smoking in pregnancy.  
The score that we developed is intended for studies with Illumina450K methylation data. For 
studies with the new IlluminaEPIC array, the score can be directly applied using the CpGs from 
our score that overlap with those on the IlluminaEPIC array with little loss of performance. Our 
work also allows comparison with a naïve method based not on any dimension reduction method 
but simply on three replicated top loci from Joubert et al. (2012). Interestingly, this naïve three 
CpG score performed relatively well given how little epigenetic information was included 
(training accuracy 82% versus 96% from the LASSO). For studies without Illumina450K or 
IlluminaEPIC data, this score could be implemented by assessing methylation at these three loci 
using pyrosequencing or other methods (Roessler and Lehmann 2015; Wani and Aldape 2016; 
Wiencke et al. 2014).  
Previous studies have developed biomarkers of smoking in adults from methylation data. 
Shenker et al. (2013) developed a methylation index based on a linear combination of 
methylation values of four CpGs and the coefficients from their genome-wide analysis. Zhang et 
al. (2015) developed a biomarker based on two CpGs that were strongly associated with all-
cause, cardiovascular, and cancer mortality. Philibert et al. (2015) investigated the use of five 
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CpGs as potential indicators of smoking for use in clinical settings. We developed a biomarker of 
sustained smoking in pregnancy using genome-wide data, which retained a larger number of 
CpGs (q=28). While there are several dimension reduction methods to choose from, we chose 
LASSO because it generally selects a more parsimonious set of features and it is difficult to 
show a significant difference in performance between the methods (Hastie et al. 2009). This 
smaller set of CpGs expected to be selected by the LASSO allows the smoking methylation score 
to be more easily implemented in other studies.  
Recent studies have shown that many of the smoking methylation signals seen in newborns 
persist into childhood. For example, the three CpGs in our naïve score are also related to 
sustained maternal smoking during pregnancy in several studies of older children, but the effects 
are attenuated with the passage of time (Küpers et al. 2015; Ladd-Acosta et al. 2016; Lee et al. 
2015; Richmond et al. 2015). 
The smoking methylation score provides studies that lack cotinine values or have incomplete 
self-reported smoking histories with an easy to calculate, objective biomarker in newborns of 
having a mother who smoked during most of the pregnancy as well as a validation of self-
reported non-smoking. It can be used to fill in missing data on smoking or its timing throughout 
pregnancy. A biomarker is superior to statistical methods to fill in missing data, such as multiple 
imputation. Our score is simple to compute in other newborn datasets with Illumina450K or 
IlluminaEPIC methylation data to generate a biomarker in newborns of sustained smoking in 
pregnancy. The score is a simple linear combination of the methylation values of 28 CpGs and a 
vector of logistic LASSO regression coefficients, which we have provided in Supplementary 
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Table S1. It is known that positive self-reports of smoking are reliable but that some smokers 
may falsely deny smoking. Because of the well-publicized adverse effects of smoking during 
pregnancy on offspring, pregnant smokers are more likely to deny smoking than other smokers 
of reproductive age who are not pregnant (Dietz et al. 2011; Kvalvik et al. 2012). Thus in 
studying effects of maternal smoking in pregnancy on health outcomes in children or adjusting 
for smoking effects in studies of other risk factors that often have more subtle effects, having an 
objective biomarker to aid in classification of smoking status is useful.  
A biomarker of sustained smoking during pregnancy will also be useful in studies of childhood 
health outcomes where DNA can be obtained from routinely collected neonatal blood spots. 
Concomitant information on smoking in birth certificates or medical charts is often limited to yes 
or no during pregnancy and may have large numbers of missing values. Smoking during 
pregnancy queried several years later when children have had time to develop conditions that are 
known to be related to parental smoking is subject to biased reporting.  
We previously reported that sustained maternal smoking during pregnancy has a much greater 
effect on newborn methylation than smoking that ceased early in pregnancy (Joubert et al. 2014). 
Here we show that “sustained smoking during pregnancy” had a greater effect on birth weight 
than “any smoking during pregnancy” which was not significantly related to birth weight. The 
smoking methylation score we developed, which reflects sustained rather than any smoking, may 
better capture health effects of maternal smoking on the newborn as our birth weight analysis 
suggests.  
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Given the large and reproducible impact of maternal smoking on the newborn methylome, there 
is great interest in whether these signals mediate health outcomes causally linked to this 
exposure, such as reduced birth weight (Küpers et al. 2015). However, regardless of whether 
they are mediators, these methylation signals are useful biomarkers of in utero exposure. The 
success of this approach for smoking, where methylation signals are abundant, augurs well for 
the use of the methylation data to develop objective biomarkers of in utero exposures that are 
harder to measure and may have subtler effects on the epigenome and child health outcomes.  
We note that the smoking methylation score was developed using data from a homogenous 
population from Norway. Therefore we do not know how generalizable it would be to other 
ethnic groups. However, the training and test methylation datasets were generated at different 
time points in different analytic batches spaced about two years apart. Thus our finding of good 
performance of the score in the test set incorporates the effects of laboratory variability 
increasing the applicability to other studies.  
To develop the score, we used data that were not normalized (not corrected for the fact that the 
Illumina450K includes two probe types). We did this both for comparability with our previous 
publication (Joubert et al. 2012) and to increase generalizability to studies that may not have 
normalized or used varying normalization procedures. We found that normalizing using the 
popular BMIQ method (Teschendorff et al. 2013) does not influence the smoking results in our 
data (Joubert et al. 2014). In addition, Wu et al. (2014), using our data, found that when 
examining an association with a high level of statistical significance, such as maternal smoking 
in pregnancy, results using raw versus normalized data are very similar. In addition, we did not 
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batch correct the test and training sets which were analyzed at different points in time. We did 
this to better approximate how the score will behave in other studies to increase generalizability 
of our results. For investigators who might want to normalize to our data, we provide the mean 
methylation values for the set of CpGs used in the score in our Supplementary Materials 
(Supplementary Table S9).  
As a supplemental analysis, we performed the LASSO method using the log ratios, rather than 
the untransformed methylation beta values, and the model performance was virtually identical 
(Training: untransformed accuracy=0.96 vs. log ratio accuracy=0.95; Test: untransformed 
accuracy=0.91 vs. log ratio accuracy=0.91; see Supplementary Table S6), however it retained 
more CpGs (37 vs. 28). A score with fewer elements is easier to use, but for users who prefer to 
analyze their data on the log ratio scale we provide a supplementary table with the 37 CpGs and 
their coefficients (Supplementary Table S10). 
We refer to our primary exposure metric, based on the combination of a positive self report and 
cotinine measured in samples taken at approximately 18 weeks, as “sustained smoking” because 
most women who reported that they had smoked in early pregnancy but quit later, had done so 
by 18 weeks. However, to determine sustained smoking, it would have been better to have 
measured cotinine again near the end of pregnancy.   
A limitation in developing a methylation score biomarker of sustained smoking during 
pregnancy is that there is no clear gold standard. Cotinine is only a reliable biomarker of recent 
smoking. We primarily used cotinine to train the model (since only a few cotinine-based non-
smokers were switched to smokers based on self-report) and thus our score cannot perform better 
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than cotinine. This removes our ability to discern whether the methylation score is truly superior 
to cotinine, a short-term biomarker, in predicting health effects of sustained maternal smoking on 
birth weight or other outcomes.  
Conclusions 
We have developed a novel biomarker in the newborn of exposure to sustained maternal 
smoking during pregnancy using Illumina450K DNA methylation data. This methylation score is 
an objective biomarker that reflects much longer-term exposure than cotinine, the best available 
smoking biomarker. The score can be easily implemented in other studies with similar 
methylation data. It provides a means to validate self-reported non-smoking status during 
pregnancy and enables the ascertainment of sustained smoking when limited time course 
information was collected. This biomarker of sustained smoking during pregnancy should 
facilitate better adjustment for maternal smoking in studies of other in utero exposures with more 
subtle effects and may improve the ability to capture novel health effects caused by this 
important prenatal exposure.  
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Table 1: Descriptive statistics of sustained smoking variables, cotinine, and quantity smoked  
Variable Category Training 
(MoBa1; N=1,057) 
Test 
(MoBa2; N=221) 
Cotinine-based sustained 
smoking; n (%)a 
No 930 (88.0) 191 (86.4) 
Yes 127 (12.0) 30 (13.6) 
Self-reported sustained smoking; 
n (%) 
No 936 (88.6) 191 (86.4) 
Yes 121 (11.4) 30 (13.6) 
Combined sustained smoking; n 
(%) 
No 920 (87.0) 190 (86.0) 
Yes 137 (13.0) 31 (14.0) 
Cotinine values by sustained 
smoking categoryb (mean ± SD) 
No 0.7 ± 3.4  0.7± 2.2 
Yes 424± 337 497 ± 301 
Number of cigarettes per day 
(among smokersb; median (IQR)) 
 5 (2-10) 5 (3-7) 
a Based on cotinine measured in maternal plasma collected at about 18 weeks of pregnancy, 
values >56.8 nmol/L classified as Yes.  
b Based on the combined sustained smoking variable.  
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Table 2: Logistic LASSO results for main and additional analyses – The number of CpGs (q) 
used to calculate the smoking methylation score, area under the curve (AUC) and 95% 
confidence interval (CI), smoking methylation score threshold, accuracy and CI, sensitivity and 
CI, specificity and CI, and number and percentage of false negatives (FN) and false positives 
(FP). 
Model q AUC 
(CI) 
Threshold Accuracy 
(CI) 
Sensitivity 
(CI) 
Specificity 
(CI) 
FN 
(%) 
FP 
(%) 
a Cotinine-based 
Sustained 
Smoking  
Trainingc 24 0.97 
(0.95,0.99) 
-9.09 0.95 
(0.94,0.97) 
0.83 
(0.76,0.89) 
0.97 
(0.96,0.98) 
22 
(2.1) 
27 
(2.6) 
 Testc 0.88 
(0.80,0.96) 
0.90 
(0.86,0.93) 
0.63 
(0.47,0.80) 
0.94 
(0.90,0.97) 
11 
(5.0) 
12 
(5.4) 
b Self-reported  
Sustained 
Smoking  
Trainingc 12 0.93 
(0.90,0.96) 
-11.71 0.92 
(0.90,0.94) 
0.81 
(0.74,0.88) 
0.93 
(0.92,0.95) 
23 
(2.2) 
64 
(6.0) 
 Testc 0.82 
(0.74,0.91) 
0.90 
(0.86,0.93) 
0.47 
(0.30,0.63) 
0.96 
(0.94,0.99) 
16 
(7.2) 
7 
(3.2) 
c Combined  
Sustained 
Smokinga 
Trainingc 28 0.96 
(0.95,0.98) 
-0.37 0.96 
(0.94,0.97) 
0.80 
(0.74,0.87) 
0.98 
(0.97,0.99) 
27 
(2.6) 
19 
(1.8) 
 Testc 0.90 
(0.83,0.97) 
0.91 
(0.88,0.95) 
0.58 
(0.39,0.74) 
0.97 
(0.94,0.99) 
13 
(5.9) 
6 
(2.7) 
d Naïve CpG 
selectionb 
Trainingc 3 0.89 
(0.86,0.92) 
-0.47 0.82 
(0.80,0.84) 
0.81 
(0.74,0.87) 
0.82 
(0.80,0.85) 
24 
(2.3) 
166 
(15.7) 
 Testc 0.82 
(0.73,0.91) 
0.83 
(0.78,0.88) 
0.60 
(0.43,0.77) 
0.87 
(0.82,0.92) 
12 
(5.4) 
25 
(11.3) 
a In the combined sustained smoking variable, a woman’s positive report of daily smoking during pregnancy overrides a cotinine 
value of ≤56.8 nmol/L used to classify a woman as a non-smoker in the cotinine-based sustained smoking variable.  
b Naïve CpG selection refers to the smoking score calculated using the three CpGs from the loci replicated at strict Bonferroni 
significance in Joubert et al. (2012). These CpGs and corresponding coefficients are cg05575921 (-0.558; AHRR), cg14179389 (-
0.555; GFI1), cg18092474 (0.205; CYP1A1). 
c Training N=1,057; Test N=221.  
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Table 3: Birth weight regression analysis results on the training data (N=1,039) – Coefficient, 
standard error (SE), and linear model p-value (PLM) for each model with a smoking variable, and 
Akaike information criterion (AIC), log likelihood (logL), likelihood-ratio test to the crude 
model, p-value (PLRT), and root mean squared error (RMSE) for each modela. 
Model Coefficient SE PLMb AIC logL PLRTc RMSE 
Crude NA NA NA 15645.5 -7812.8 NA 446.11 
Methylation Score 
Class 
-130.9 42.81 0.0023 15638.1 -7808.1 0.0022 444.10 
Cotinine-based  
Sustained Smoking  
-133.3 44.08 0.0026 15638.3 -7808.2 0.0024 444.14 
Self-reported  
Sustained Smoking  
-120.4 44.95 0.0075 15640.3 -7809.2 0.0072 444.56 
Combined  
Sustained Smokingb 
-131.4 42.62 0.0021 15638.0 -7808.0 0.0020 444.06 
Self-reported  
Any Smoking  
-48.2 32.18 0.1348 15645.3 -7811.6 0.1329 445.62 
a All models adjusted for gender, gestational age, maternal education, maternal age, parity, and 
selection. 
b In the combined sustained smoking variable, a woman’s self-report of daily smoking during 
pregnancy overrides a cotinine value of ≤56.8 nmol/L used to classify a woman as a non-smoker 
in the cotinine-based sustained smoking variable.  
c p-values<0.05 were considered to represent statistical significance. 
